A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE010 (ESP) · Dr. Silva
consented 2023-03-19
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Grade 2 Decreased appetite — outcome: RECOVERED/RESOLVED; onset 2023-04-11 (study day 12); relationship: Y
severe
assessed
Grade 3 Neutropenia — outcome: RECOVERED/RESOLVED; onset 2023-08-27 (study day 150); relationship: N
mild
assessed
Grade 1 Stomatitis — outcome: RECOVERED/RESOLVED; onset 2023-12-15 (study day 260); relationship: not assessed
Data queries
No data queries.